152 related articles for article (PubMed ID: 2429667)
1. Sequence-, time- and dose-dependent synergism of methotrexate and 6-mercaptopurine in malignant human T-lymphoblasts.
Bökkerink JP; Bakker MA; Hulscher TW; De Abreu RR; Schretlen ED; van Laarhoven JP; De Bruyn CH
Biochem Pharmacol; 1986 Oct; 35(20):3549-55. PubMed ID: 2429667
[TBL] [Abstract][Full Text] [Related]
2. Purine de novo synthesis as the basis of synergism of methotrexate and 6-mercaptopurine in human malignant lymphoblasts of different lineages.
Bökkerink JP; Bakker MA; Hulscher TW; De Abreu RA; Schretlen ED
Biochem Pharmacol; 1988 Jun; 37(12):2321-7. PubMed ID: 2455519
[TBL] [Abstract][Full Text] [Related]
3. 6-Mercaptopurine: cytotoxicity and biochemical pharmacology in human malignant T-lymphoblasts.
Bökkerink JP; Stet EH; De Abreu RA; Damen FJ; Hulscher TW; Bakker MA; van Baal JA
Biochem Pharmacol; 1993 Apr; 45(7):1455-63. PubMed ID: 7682415
[TBL] [Abstract][Full Text] [Related]
4. Dose-related effects of methotrexate on purine and pyrimidine nucleotides and on cell-kinetic parameters in MOLT-4 malignant human T-lymphoblasts.
Bökkerink JP; De Abreu RA; Bakker MA; Hulscher TW; Van Baal JM; De Vaan GA
Biochem Pharmacol; 1986 Oct; 35(20):3557-64. PubMed ID: 2429668
[TBL] [Abstract][Full Text] [Related]
5. On the biochemical modulation of 6-mercaptopurine by methotrexate in murine WEHI-3b leukemia cells in vitro.
Liliemark J; Pettersson B; Peterson C
Leuk Res; 1992; 16(3):275-80. PubMed ID: 1373210
[TBL] [Abstract][Full Text] [Related]
6. [6-Mercaptopurine and methotrexate, rational use in sight after 35 years?].
Bökkerink JP; Schouten TJ; De Abreu RA; Lippens RJ; De Vaan GA; De Bruyn CH; Van Laarhoven JP
Tijdschr Kindergeneeskd; 1984 Aug; 52(4):118-23. PubMed ID: 6593896
[TBL] [Abstract][Full Text] [Related]
7. Methotrexate inhibits the first committed step of purine biosynthesis in mitogen-stimulated human T-lymphocytes: a metabolic basis for efficacy in rheumatoid arthritis?
Fairbanks LD; Rückemann K; Qiu Y; Hawrylowicz CM; Richards DF; Swaminathan R; Kirschbaum B; Simmonds HA
Biochem J; 1999 Aug; 342 ( Pt 1)(Pt 1):143-52. PubMed ID: 10432311
[TBL] [Abstract][Full Text] [Related]
8. [Biochemical and clinico-pharmacological aspects of antimetabolites in the treatment of leukemia].
Bökkerink JP; de Abreu RA; Lippens RJ; Schouten TJ; de Vaan GA
Tijdschr Kindergeneeskd; 1988 Apr; 56(2):55-60. PubMed ID: 3287684
[TBL] [Abstract][Full Text] [Related]
9. Cell-kinetics and biochemical pharmacology of methotrexate and 6-mercaptopurine in human malignant T-lymphoblasts.
Bökkerink JP; De Abreu RA; Stet EH; Damen FJ
Klin Padiatr; 1992; 204(4):293-8. PubMed ID: 1518268
[TBL] [Abstract][Full Text] [Related]
10. Effects of methotrexate on purine and pyrimidine metabolism and cell-kinetic parameters in human malignant lymphoblasts of different lineages.
Bökkerink JP; De Abreu RA; Bakker MA; Hulscher TW; van Baal JM; Schretlen ED; De Bruijn CH
Biochem Pharmacol; 1988 Jun; 37(12):2329-38. PubMed ID: 2455520
[TBL] [Abstract][Full Text] [Related]
11. [Use of purine rescue pathways by L1210 cells exposed to methotrexate in vitro].
Buesa JM
Rev Esp Oncol; 1982; 29(4):641-7. PubMed ID: 6085740
[TBL] [Abstract][Full Text] [Related]
12. Effects of methotrexate on nucleotide pools in normal human T cells and the CEM T cell line.
Budzik GP; Colletti LM; Faltynek CR
Life Sci; 2000; 66(23):2297-307. PubMed ID: 10855951
[TBL] [Abstract][Full Text] [Related]
13. Reversal of 6-mercaptopurine and 6-methylmercaptopurine ribonucleoside cytotoxicity by amidoimidazole carboxamide ribonucleoside in Molt F4 human malignant T-lymphoblasts.
Stet EH; De Abreu RA; Bökkerink JP; Vogels-Mentink TM; Lambooy LH; Trijbels FJ; Trueworthy RC
Biochem Pharmacol; 1993 Aug; 46(3):547-50. PubMed ID: 8347177
[TBL] [Abstract][Full Text] [Related]
14. The importance of methylthio-IMP for methylmercaptopurine ribonucleoside (Me-MPR) cytotoxicity in Molt F4 human malignant T-lymphoblasts.
Vogt MH; Stet EH; De Abreu RA; Bökkerink JP; Lambooy LH; Trijbels FJ
Biochim Biophys Acta; 1993 Apr; 1181(2):189-94. PubMed ID: 7683208
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of two enzymes in de novo purine nucleotide synthesis by triciribine phosphate (TCN-P).
Moore EC; Hurlbert RB; Boss GR; Massia SP
Biochem Pharmacol; 1989 Nov; 38(22):4045-51. PubMed ID: 2480792
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of CCRF-CEM human leukemic lymphoblasts by triciribine (tricyclic nucleoside, TCN, NSC-154020). Accumulation of drug in cells and comparison of effects on viability, protein synthesis and purine synthesis.
Moore EC; Hurlbert RB; Massia SP
Biochem Pharmacol; 1989 Nov; 38(22):4037-44. PubMed ID: 2480791
[TBL] [Abstract][Full Text] [Related]
17. Alteration of purine metabolism by AICA-riboside in human B lymphoblasts.
Barankiewicz J; Jimenez R; Ronlov G; Magill M; Gruber HE
Arch Biochem Biophys; 1990 Nov; 282(2):377-85. PubMed ID: 1700665
[TBL] [Abstract][Full Text] [Related]
18. Glutamine requirements for purine metabolism in leukemic lymphoblasts.
Raivio KO; Andersson LC
Leuk Res; 1982; 6(1):111-5. PubMed ID: 6978431
[TBL] [Abstract][Full Text] [Related]
19. Biochemical parameters of mercaptopurine activity in patients with acute lymphoblastic leukemia.
Zimm S; Reaman G; Murphy RF; Poplack DG
Cancer Res; 1986 Mar; 46(3):1495-8. PubMed ID: 2417705
[TBL] [Abstract][Full Text] [Related]
20. Fibroblast growth factor-dependent metabolism of hypoxanthine via the salvage pathway for purine synthesis in porcine aortic endothelial cells.
Hirai S; Hayashi Y; Koizumi T; Nakanishi N; Fukui T; Ichikawa A
Biochem Pharmacol; 1993 Apr; 45(8):1695-701. PubMed ID: 7683470
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
